Lumenis Ltd. Showcases UltraPulse® With Advanced Resurfacing at the Scar Revision Luncheon During ASLMS 2013

YOKNEAM, ISRAEL--(Marketwired - April 04, 2013) - Lumenis Ltd., announces its participation in the 33rd Annual Conference of the American Society for Laser Medicine and Surgery (ASLMS), presenting its UltraPulse system’s SCAAR FX™ (Synergistic Coagulation and Ablation for Advanced Resurfacing) modality at the conference. ASLMS will take place at the Sheraton Boston Hotel / Hynes Convention Center in Boston, MA, USA, from April 3-7, 2013.

SCAAR FX treats a variety of conspicuous, complex, deep skin lesions that require synergistic coagulation and ablation for advanced resurfacing, including acne and surgical scars.

Compared to other CO2 lasers on the market that reach a depth of only 1 mm per pulse, SCAAR FX facilitates direct impact up to four (4) millimeters deep. Using precision and high-energy impact (up to 150 mJ per pulse per spot), and an optimized ablation/coagulation ratio. UltraPulse significantly improves the structure of deep, contracted skin lesions, enhances skin appearance, and increases range of motion, while causing minimal side effects. (1, 2)

According to Dr. Matthias Donelan, Chief of Plastic Surgery at the Shriners Hospital for Children, and Associate Clinical Professor of Surgery at Harvard Medical School in Boston, MA, USA, “I have been treating patients, primarily children, with scarring following burns and other types of trauma for over 35 years and there is a huge unmet need for non-invasive ways to enhance their quality of life and self-esteem. The use of the UltraPulse has further enhanced our ability to rehabilitate scars both functionally and in their appearance.”

Lumenis also announced that it will launch the “HOPE” Campaign at the ASLMS Conference, by presenting patient testimonials. The HOPE Campaign will feature a range of patient stories describing how the laser treatment with UltraPulse improved their lives. One young burn victim featured in the HOPE Campaign will attend ASLMS on April 5, 2013 to talk about her personal experience.

Lumenis is also donating a SCAAR FX upgrade to a Lumenis UltraPulse, for the silent auction that will be held at ASLMS. This upgrade may enable physicians to offer a significantly better quality of life for patients with deep skin lesions requiring advanced modality such as conspicuous scars, as well as for aesthetics. The package, valued at $10,000, includes hardware, software, on-site installation, user manual, SCAAR FX Quick Reference Guide, clinical training, and a preventative maintenance check on the entire UltraPulse system.

Mr. Roy Ramati, Vice President & General Manager of the Aesthetic Business Unit at Lumenis, stated, “We are thrilled to participate at the ASLMS eighth annual Silent Auction by donating the SCAAR FX upgrade to support scientific Research. Supporting this activity is consistent with our objective of developing innovative medical solutions that improve the wellbeing and enhance the lives of patients. Ever since its market introduction, the UltraPulse SCAAR FX upgrade has received wide recognition from physicians for its remarkable capabilities to address both aesthetic and functional challenges in the field of scar treatment.”

Drs. Jill Waibel and Nathan Uebelhoer will be co-directing the “Scar Wars” Scar Revision Luncheon on April 4, 2013 from 12:15 pm-1:15 pm in the Commonwealth room. Lumenis’ technology will be featured during this event. Additional information about this session can be found at the following link: http://www.aslms.org/annualconference/scarrevision.shtml

We encourage physicians to learn more about Lumenis’ extensive product line including SCAAR FX™ UltraPulse®, AcuPulse™, QX-Max, VaserShape®, LightSheer® Duet™, and M22™, at Booth #619 throughout the conference.

About Lumenis

Lumenis, the world’s largest medical laser company, is a global developer, manufacturer and distributor of laser and light-based devices for surgical, aesthetic and ophthalmic applications, with more than 900 employees worldwide. Lumenis has 265 registered patents, over 260 FDA clearances, an install base of over 80,000 systems and presence in over 80 countries. Lumenis endeavors to bring the finest state of the art technology products to the market, fulfilling the highest standards of excellence, quality and reliability, delivering premium value and service to its customers. The name Lumenis is derived from a Latin word meaning “Light of Life.” Highlighting the light is the basis of our technologies used to enhance life. For more information about Lumenis and its products, please visit: www.lumenis.com.

Lumenis® and the Lumenis logo are trademarks or registered trademarks of Lumenis.

1. Waibel J, Beer K., Ablative fractional laser resurfacing for the treatment of a third-degree burn, Journal of Drugs in Dermatology, 2009, 8(3):294-297.

2. Cho, S.B., et al, Treatment of burn scar using carbon dioxide fractional laser, Journal of Drugs in Dermatology, 2010, 9(2):1-3.